Siemens PETNET Solutions has expanded manufacturing and distribution of the amyloid-targeting imaging agent F-18 Florbetapir (Amyvid) to 17 sites.
This increases availability of the PET tracer to eight metropolitan areas across the PETNET Solutions network, including Los Angeles, Boston, Minneapolis, Fort Lauderdale, Fla. and Cleveland. The agent is also being produced and shipped out of Raleigh, N.C., and Hackensack, N.J.
Manufacturing and distribution of the Eli Lilly radiopharmaceutical continues in Chicago, Dallas, Houston, Atlanta, Seattle, Philadelphia and St. Louis, Mo. as well as Palo Alto, Calif., And Jacksonville, Fla.
Amyvid was approved by the FDA for PETimaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline in April 2012. Amyvid was first made available to imaging centers in markets surrounding 16 manufacturing sites in the U.S. in June 2012.